Cancer Immunology Immunotherapy

Papers
(The TQCC of Cancer Immunology Immunotherapy is 16. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-11-01 to 2025-11-01.)
ArticleCitations
Correction to: CD33 BiTE® molecule-mediated immune synapse formation and subsequent T-cell activation is determined by the expression profile of activating and inhibitory checkpoint molecules on AML c125
Risk factors indicating immune-related adverse events with combination chemotherapy with immune checkpoint inhibitors and platinum agents in patients with non-small cell lung cancer: a multicenter ret117
A nanotherapeutic system for gastric cancer suppression by synergistic chemotherapy and immunotherapy based on iPSCs and DCs exosomes93
Tumor-associated macrophages as a potential therapeutic target in thyroid cancers87
Hypertransaminasemia in cancer patients receiving immunotherapy and immune-based combinations: the MOUSEION-05 study84
Host B cells escape CAR-T immunotherapy by reversible downregulation of CD1969
Elotuzumab, a potential therapeutic humanized anti-SLAMF7 monoclonal antibody, enhances natural killer cell-mediated killing of primary effusion lymphoma cells62
OIT3 mediates macrophage polarization and facilitates hepatocellular carcinoma progression62
PD-L1 expression on immune cells, but not on tumor cells, is a favorable prognostic factor for patients with intrahepatic cholangiocarcinoma58
A Novel bispecific T-cell engager (BiTE) targeting CD22 and CD3 has both in vitro and in vivo activity and synergizes with blinatumomab in an acute lymphoblastic leukemia (ALL) tumor model52
Targeting PD-L1 and TIGIT could restore intratumoral CD8 T cell function in human colorectal cancer49
Expansion of KRAS hotspot mutations reactive T cells from human pancreatic tumors using autologous T cells as the antigen-presenting cells46
Clinical trials of neoadjuvant immune checkpoint inhibitors for early-stage operable colon and rectal cancer45
Allogeneic CAR-T cells with of HLA-A/B and TRAC disruption exhibit promising antitumor capacity against B cell malignancies44
Camrelizumab combined with apatinib and S-1 as second-line treatment for patients with advanced gastric or gastroesophageal junction adenocarcinoma: a phase 2, single-arm, prospective study43
A randomised controlled trial of long NY-ESO-1 peptide-pulsed autologous dendritic cells with or without alpha-galactosylceramide in high-risk melanoma43
Cytokine alterations during paraneoplastic neutrophilia and leukemoid reaction in patients with advanced melanoma42
High DKK3 expression related to immunosuppression was associated with poor prognosis in glioblastoma: machine learning approach41
Safety and efficacy of the anti-PD1 immunotherapy with nivolumab in trichoblastic carcinomas40
Robust immune response stimulated by in situ injection of CpG/αOX40/cGAMP in αPD-1-resistant malignancy39
Costimulatory molecule expression profile as a biomarker to predict prognosis and chemotherapy response for patients with small cell lung cancer39
Factors impacting the efficacy of the in-situ vaccine with CpG and OX40 agonist38
Establishment of a mechanism-based in vitro coculture assay for evaluating the efficacy of immune checkpoint inhibitors38
Reovirus combined with a STING agonist enhances anti-tumor immunity in a mouse model of colorectal cancer36
Blood DCs activated with R848 and poly(I:C) induce antigen-specific immune responses against viral and tumor-associated antigens35
Endosialin-positive tumor-derived pericytes promote tumor progression through impeding the infiltration of CD8+ T cells in clear cell renal cell carcinoma35
Use of concomitant proton pump inhibitors, statins or metformin in patients treated with pembrolizumab for metastatic urothelial carcinoma: data from the ARON-2 retrospective study35
Lymphodepleting chemotherapy practices and effect on safety and efficacy outcomes in patients with solid tumours undergoing T cell receptor-engineered T cell (TCR-T) Therapy: a systematic review and m35
Bis-indole-derived NR4A1 antagonists inhibit colon tumor and splenic growth and T-cell exhaustion35
Toxicity-specific peripheral blood T and B cell dynamics in anti-PD-1 and combined immune checkpoint inhibition34
Enhancement of CD70-specific CAR T treatment by IFN-γ released from oHSV-1-infected glioblastoma34
A retrospective real-world study: the efficacy of immune-related combination therapies in advanced non-small cell lung cancer after resistance to EGFR-TKIs31
Using EGFR amplification to stratify recurrent glioblastoma treated with immune checkpoint inhibitors31
Preclinical development of a vaccine-based immunotherapy regimen (VBIR) that induces potent and durable T cell responses to tumor-associated self-antigens30
Combination therapy with dendritic cell loaded-exosomes supplemented with PD-1 inhibition at different time points have superior antitumor effect in hepatocellular carcinoma30
Near-infrared photoimmunotherapy induced tumor cell death enhances tumor dendritic cell migration30
Engineered soluble, trimerized 4-1BBL variants as potent immunomodulatory agents30
Chemical screening identifies novel small molecule activators of natural killer cell cytotoxicity against cancer cells30
Improvement of STING-mediated cancer immunotherapy using immune checkpoint inhibitors as a game-changer29
Epstein-Barr virus-induced ectopic CD137 expression helps nasopharyngeal carcinoma to escape immune surveillance and enables targeting by chimeric antigen receptors29
CXCL9-modified CAR T cells improve immune cell infiltration and antitumor efficacy28
Baseline tumour size is an independent prognostic factor for overall survival in PD-L1 ≥ 50% non-small cell lung cancer patients treated with first-line pembrolizumab28
TIM-3 as a promising target for cancer immunotherapy in a wide range of tumors28
Systemic administration of STING agonist promotes myeloid cells maturation and antitumor immunity through regulating hematopoietic stem and progenitor cell fate28
Oncolytic attenuated measles virus encoding NY-ESO-1 induces HLA I and II presentation of this tumor antigen by melanoma and dendritic cells27
Radiation-associated secondary malignancies: a novel opportunity for applying immunotherapies27
Correction to: Myeloid-derived suppressor cells cross-talk with B10 cells by BAFF/BAFF-R pathway to promote immunosuppression in cervical cancer27
Effectiveness of pembrolizumab in trial-ineligible patients with metastatic urothelial carcinoma27
GK-1 effectively reduces angiogenesis and prevents T cell exhaustion in a breast cancer murine experimental model27
Cytokine profiling identifies circulating IL-6 and IL-15 as prognostic stratifiers in patients with non-small cell lung cancer receiving anti-PD-1/PD-L1 blockade therapy26
Neoadjuvant Camrelizumab for Non-Small Cell Lung Cancer: A Retrospective Multicenter, Real-World Study (CTONG2004)26
Generation of NK cells with chimeric-switch receptors to overcome PD1-mediated inhibition in cancer immunotherapy26
Blockade of IL-1α and IL-1β signaling by the anti-IL1RAP antibody nadunolimab (CAN04) mediates synergistic anti-tumor efficacy with chemotherapy26
Personalized tumor vaccine for pancreatic cancer26
Effect of genetic polymorphisms on outcomes following nivolumab for advanced renal cell carcinoma in the SNiP-RCC trial26
Pre-treatment serum protein levels predict survival of non-small cell lung cancer patients without durable clinical benefit by PD-1/L1 inhibitors26
Pharmacological potentiation of monocyte-derived dendritic cell cancer immunotherapy25
Combined treatment with anti-HER2/neu and anti-4-1BB monoclonal antibodies induces a synergistic antitumor effect but requires dose optimization to maintain immune memory for protection from lethal re25
Identification of the molecular subtype and prognostic characteristics of pancreatic cancer based on CD8 + T cell-related genes25
Cancer immunity and immunotherapy beyond COVID-1925
A Phase I-II multicenter trial with Avelumab plus autologous dendritic cell vaccine in pre-treated mismatch repair-proficient (MSS) metastatic colorectal cancer patients; GEMCAD 1602 study25
Correction to: Nivolumab versus placebo as adjuvant therapy for resected stage III melanoma: a propensity weighted indirect treatment comparison and number needed to treat analysis for recurrence-free24
A Fc-VEGF chimeric fusion enhances PD-L1 immunotherapy via inducing immune reprogramming and infiltration in the immunosuppressive tumor microenvironment24
LILRB2-containing small extracellular vesicles from glioblastoma promote tumor progression by promoting the formation and expansion of myeloid-derived suppressor cells23
Identification of HLA-A2 restricted epitopes of glypican-3 and induction of CTL responses in HLA-A2 transgenic mice23
Serial interferon-gamma release assay in lung cancer patients receiving immune checkpoint inhibitors: a prospective cohort study23
Taurine enhances the antitumor efficacy of PD-1 antibody by boosting CD8+ T cell function23
Comprehensive analysis of the immunological implication and prognostic value of CXCR4 in non-small cell lung cancer23
Associations between KIR/KIR-ligand genotypes and clinical outcome for patients with advanced solid tumors receiving BEMPEG plus nivolumab combination therapy in the PIVOT-02 trial23
Single-cell analysis of peripheral CD8+ T cell responses in patients receiving checkpoint blockade immunotherapy for cancer23
Rescue of NLRC5 expression restores antigen processing machinery in head and neck cancer cells lacking functional STAT1 and p5323
Brain metastases and immune checkpoint inhibitors in non-small cell lung cancer: a systematic review and meta-analysis22
The role of spatial interplay patterns between PD-L1-positive tumor cell and T cell in recurrence of locally advanced non-small cell lung cancer22
PD-1 Inhibitors combined with paclitaxel (Albumin-bound) and cisplatin for larynx preservation in locally advanced laryngeal and hypopharyngeal squamous cell carcinoma: a retrospective study22
Revealing the impact of CD70 expression on the manufacture and functions of CAR-70 T-cells based on single-cell transcriptomics22
Organ-on-a-chip models for development of cancer immunotherapies22
Cancer bio-immunotherapy XVIII annual NIBIT-(Italian network for tumor biotherapy) meeting, October 15–16, 202022
TCR extracellular domain genetically linked to CD28, 2B4/41BB and DAP10/CD3ζ -engineered NK cells mediates antitumor effects21
Comprehensive analyses of prognostic biomarkers and immune infiltrates among histone lysine demethylases (KDMs) in hepatocellular carcinoma21
Immune checkpoint inhibition combined with targeted therapy using a novel virus-like drug conjugate induces complete responses in a murine model of local and distant tumors21
Immune-related adverse events of COVID-19 vaccination in skin cancer patients receiving immune-checkpoint inhibitor treatment21
Tumour cell-activated platelets modulate the immunological activity of CD4+, CD8+, and NK cells, which is efficiently antagonized by heparin21
Live attenuated VZV vaccination induces antitumor immunity in ATLL patients21
Peptide vaccine from cancer-testis antigen ODF2 can potentiate the cytotoxic T lymphocyte infiltration through IL-15 in non-MSI-H colorectal cancer21
Metformin inhibits human non-small cell lung cancer by regulating AMPK–CEBPB–PDL1 signaling pathway21
Inflammasome activation, NLRP3 engagement and macrophage recruitment to tumor microenvironment are all required for Salmonella antitumor effect21
Pretreatment blast-to-lymphocyte ratio as a prognostic marker for CD19/CD3-bispecific T cell-engaging antibodies (blinatumomab) treatment against relapsed or refractory B-precursor acute lymphoblastic20
Phellinus linteus activates Treg cells via FAK to promote M2 macrophage polarization in hepatocellular carcinoma20
Local radiotherapy and E7 RNA-LPX vaccination show enhanced therapeutic efficacy in preclinical models of HPV16+ cancer20
Generation and assessment of cytokine-induced killer cells for the treatment of colorectal cancer liver metastases20
Radiation-induced dormancy of intracerebral melanoma: endotoxin inflammation leads to both shortened tumor dormancy and long-term survival with localized senescence20
Good manufacturing practice production of CD34+ progenitor-derived NK cells for adoptive immunotherapy in acute myeloid leukemia20
Novel ocular immunotherapy induces tumor regression in an equine model of ocular surface squamous neoplasia20
SIGLEC10+ macrophages drive gastric cancer progression by suppressing CD8+ T cell function20
Interaction of glioma-associated microglia/macrophages and anti-PD1 immunotherapy19
Tumor-derived IL-8 facilitates lymph node metastasis of gastric cancer via PD-1 up-regulation in CD8+ T cells19
Immune characteristics and prognostic implications of mucosal-associated invariant T cells in acute myeloid leukemia19
Functional expression of CD73 on human natural killer cells19
STAT3 promotes differentiation of monocytes to MDSCs via CD39/CD73-adenosine signal pathway in oral squamous cell carcinoma19
Murine regulatory T cells utilize granzyme B to promote tumor metastasis18
Targeting transforming growth factor-β2 by antisense oligodeoxynucleotide accelerates T cell-mediated tumor rejection in a humanized mouse model of triple-negative breast cancer18
Invariant NKT cell-augmented GM-CSF-secreting tumor vaccine is effective in advanced prostate cancer model18
Human colorectal cancer: upregulation of the adaptor protein Rai in TILs leads to cell dysfunction by sustaining GSK-3 activation and PD-1 expression18
Successful ex vivo expansion of tumor infiltrating lymphocytes with systemic chemotherapy prior to surgical resection18
Blockade of tumor-derived colony-stimulating factor 1 (CSF1) promotes an immune-permissive tumor microenvironment18
Tumor-associated neutrophils upregulate PANoptosis to foster an immunosuppressive microenvironment of non-small cell lung cancer18
The common HLA class I-restricted tumor-infiltrating T cell response in HPV16-induced cancer18
Anti-PD-1 antibody-activated Th17 cells subvert re-invigoration of antitumor cytotoxic T-lymphocytes via myeloid cell-derived COX-2/PGE218
Altered immunity to microbiota, B cell activation and depleted γδ/resident memory T cells in colorectal cancer18
Dynamic peripheral blood immune cell markers for predicting the response of patients with metastatic cancer to immune checkpoint inhibitors18
HPV-associated head and neck cancer is characterized by distinct profiles of CD8+ T cells and myeloid-derived suppressor cells18
Multivalent adaptor proteins specifically target NK cells carrying a universal chimeric antigen receptor to ErbB2 (HER2)-expressing cancers18
A Listeria-based vaccine targeting ISG15 exerts anti-tumor efficacy in renal cell carcinoma18
Inhibition of the CCR6-CCL20 axis prevents regulatory T cell recruitment and sensitizes head and neck squamous cell carcinoma to radiation therapy17
Brachyury-targeted immunotherapy combined with gemcitabine against head and neck cancer17
Pembrolizumab near the end of life in patients with metastatic pancreatic cancer: a multi-site consecutive series to examine survival and patient treatment burden17
Improved MAIT cell functions following fecal microbiota transplantation for metastatic renal cell carcinoma17
Extracellular vesicles derived from M2-polarized tumor-associated macrophages promote immune escape in ovarian cancer through NEAT1/miR-101-3p/ZEB1/PD-L1 axis17
Combination of magnetic hyperthermia and immunomodulators to drive complete tumor regression of poorly immunogenic melanoma17
First-line single-agent pembrolizumab for PD-L1-positive (tumor proportion score ≥ 50%) advanced non-small cell lung cancer in the real world: impact in brain metastasis: a national French multicentri17
Preclinical development and evaluation of nanobody-based CD70-specific CAR T cells for the treatment of acute myeloid leukemia17
Tumor immunology meets oncology (TIMO) XVII, April 20–22 2023 in Halle/Saale, Germany17
Immunoreactivity to WT1 peptide vaccine is associated with prognosis in elderly patients with acute myeloid leukemia: follow-up study of randomized phase II trial of OCV-501, an HLA class II-binding W17
Correction to: TIGIT blockade enhances tumor response to radiotherapy via a CD103 + dendritic cell-dependent mechanism17
Targeting CD73 increases therapeutic response to immunogenic chemotherapy by promoting dendritic cell maturation16
Considerations regarding the tumor-suppressor role of naringenin as a novel agent for the treatment of oral squamous cell carcinoma16
Ziv-aflibercept plus pembrolizumab in patients with advanced melanoma resistant to anti-PD-1 treatment16
Immunosuppressive TREM2(+) macrophages are associated with undesirable prognosis and responses to anti-PD-1 immunotherapy in non-small cell lung cancer16
Correction to: Hepatotoxicity associated with PD-1 blockade antibodies in cancer patients co-infected with hepatitis B virus16
CAR γδ T cells for cancer immunotherapy. Is the field more yellow than green?16
Self-assembled nanoparticles based on DNA origami and a nitrated T helper cell epitope as a platform for the development of personalized cancer vaccines16
Cellular and soluble immune checkpoint signaling forms PD-L1 and PD-1 in renal tumor tissue and in blood16
Correction to: Increased TIGIT expressing NK cells with dysfunctional phenotype in AML patients correlated with poor prognosis16
Real-world outcomes of nivolumab plus ipilimumab and pembrolizumab with platinum-based chemotherapy in advanced non-small cell lung cancer: a multicenter retrospective comparative study16
Checkpoint-inhibitor induced Polyserositis with Edema16
Anti-PD-1 therapy in advanced sarcomas: is cutaneous primary site a stronger predictor of response than histologic subtype?16
Multidisciplinary recommendations for essential baseline functional and laboratory tests to facilitate early diagnosis and management of immune-related adverse events among cancer patients16
0.1766140460968